| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate o...
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to to...